Oral administration of pneumococcal antigens

US6004802A · kind A · utility

Assignee

• UNIVERSITY OF ALABAMA AT BIRMINGHAM · US

Inventors

• David E. Briles · Birmingham, US
• Larry S. McDaniel · Birmingham, US
• Masafumi Yamamoto · Birmingham, US
• Hiroshi Kiyono · Tokyo, JP

Key dates

• Filing date: May 30, 1996
• Grant date: Dec 21, 1999
• Expiry date: May 30, 2016

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K39/092
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Oral or peroral administration, including intragastrically, of killed whole pneumococci, lysate of pneumococci and isolated and purified PspA, as well as immunogenic fragments thereof, particularly when administered with an adjuvant such as cholera toxin provides protection in a host, animal or human, against pneumococcal infection, including colonization, and systemic infection, such as sepsis. The ability to elicit protection against pneumococcal colonization in a host prevents carriage among immunized individuals, which can lead to elimination of disease from the population as a whole.